On March 23, 2016 Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, reported that the company will host a Research Reception at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Advaxis, MAR 23, 2016, View Source [SID:1234509834]). The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Advaxis Research Reception will feature two presentations:
Lm Immunotherapy: Impact within the Tumor Microenvironment
A review of the late-breaking poster presentation (Abstract #LB-095) on the immunogenicity of Advaxis’ lead immunotherapy candidate, axalimogene filolisbac, as preoperative treatment prior to robotic-assisted surgery in patients with HPV-associated head and neck cancer.
Rosemarie Krupar, MD, Baylor College of Medicine
Immunogenicity of ADXS-HER2 in Canine Osteosarcoma
Nicola Mason, PhD, BVetMed, Assistant Professor of Medicine, University of Pennsylvania
Effects of Advaxis’ Lm Immunotherapy on the STING Pathway
Robert Petit, PhD, Chief Scientific Officer, Advaxis
Cancer Neoepitope Immunotherapy: An Update on ADXS-NEO
Robert Petit, PhD, Chief Scientific Officer, Advaxis
Attendees will also have the opportunity to view the late breaking Phase 2 poster featured at AACR (Free AACR Whitepaper) and ask questions of the lead author. Space is limited and registration, which is required, can be completed online at: www.regonline.com/advaxisreception2016.